Daniel Maslyar

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts

Thorsten Berg, Steven B. Cohen, Joel Desharnais et al. · Proceedings of the National Academy of Sciences · 2002 · 323 citations · Full text

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues et al. · Clinical Cancer Research · 2018 · 303 citations

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

James M. Burke, Donald L. Lamm, Maxwell V. Meng et al. · The Journal of Urology · 2012 · 227 citations

Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS elements

Luca Comai, Paul Moran, Daniel Maslyar · Plant Molecular Biology · 1990 · 176 citations

Plant Molecular Biology, Engineering, Chimeric Plant Promoter +10